Five-year outcomes from 3 prospective trials of image-guided proton therapy for prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 88, Issue 3, 2014, Pages 596-602

  Mendenhall, Nancy P ^a   Hoppe, Bradford S ^a   Nichols, Romaine C ^a   Mendenhall, William M ^a   Morris, Christopher G ^a   Li, Zuofeng ^a   Su, Zhong ^a   Williams, Christopher R ^b   Costa, Joseph ^b   Henderson, Randal H ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE PROGRESSION; DOSE FRACTIONATION; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTON THERAPY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, IMAGE-GUIDED; TIME FACTORS; TREATMENT OUTCOME;

EID: 84893841095     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2013.11.007     Document Type: Article

References (40)

1. M.G. Sanda, R.L. Dunn, and J. Michalski et al. Quality of life and satisfaction with outcome among prostate-cancer survivors N Engl J Med 358 2008 1250 1261 (Pubitemid 351439226)
2. D.E. Spratt, X. Pei, and J. Yamada et al. Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer Int J Radiat Oncol Biol Phys 85 2013 686 692
3. J.D. Fontenot, A.K. Lee, and W.D. Newhauser Risk of secondary malignant neoplasms from proton therapy and intensity-modulated x-ray therapy for early-stage prostate cancer Int J Radiat Oncol Biol Phys 74 2009 616 622
4. M. Yoon, S.H. Ahn, and J. Kim et al. Radiation-induced cancers from modern radiotherapy techniques: intensity-modulated radiotherapy versus proton therapy Int J Radiat Oncol Biol Phys 77 2010 1477 1485
5. J.D. Slater, C.J. Rossi Jr., and L.T. Yonemoto et al. Proton therapy for prostate cancer: the initial Loma Linda University experience Int J Radiat Oncol Biol Phys 59 2004 348 352 (Pubitemid 38622585)
6. A.L. Zietman, K. Bae, and J.D. Slater et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09 J Clin Oncol 28 2010 1106 1111
7. A.M. Allen, T. Pawlicki, and L. Dong et al. An evidence based review of proton beam therapy: the report of ASTRO's emerging technology committee Radiother Oncol 103 2012 8 11
8. J. Walsh Proton Therapy for Prostate Cancer 2012 California Technology Assessment Forum San Francisco
9. N.C. Sheets, G.H. Goldin, and A.M. Meyer et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer JAMA 307 2012 1611 1620
10. N.P. Mendenhall, Z. Li, and B.S. Hoppe et al. Early outcomes from three prospective trials of image-guided proton therapy for prostate cancer Int J Radiat Oncol Biol Phys 82 2012 213 221
11. S.B. Edge, D.R. Byrd, and C.C. Compton et al. AJCC Cancer Staging Manual Vol 7 2010 Springer
12. M. Roach 3rd, G. Hanks, and H. Thames Jr. et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 65 2006 965 974
13. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v3.0 2003. Accessed at: http://ctep.cancer.gov/protocolDevelopment/ electronic-applications/docs/ctcaev3.pdf.
14. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v4.0 2010. Accessed at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03- 2010-06-14-QuickReference-5x7.pdf.
15. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology v2.0, 2010. Accessed at: http://www.nccn.org/international/ international-adaptations.aspx.
16. U. Schneider, E. Pedroni, and A. Lomax The calibration of CT Hounsfield units for radiotherapy treatment planning Phys Med Biol 41 1996 111 124 (Pubitemid 26034228)
17. P. Ghadjar, A. Jackson, and D.E. Spratt et al. Patterns and predictors of amelioration of genitourinary toxicity after high-dose intensitymodulated radiation therapy for localized prostate cancer: implications for defining postradiotherapy urinary toxicity Eur Urol 64 2013 931 938
18. R.H. Henderson, B.S. Hoppe, and R.B. Marcus Jr. et al. Urinary functional outcomes and toxicity five years after proton therapy for low- and intermediate-risk prostate cancer: results of two prospective trials Acta Oncol 52 2013 463 469
19. K. Takeda, Y. Ogawa, and H. Ariga et al. Clinical correlations between treatment with anticoagulants/antiaggregants and late rectal toxicity after radiotherapy for prostate cancer Anticancer Res 29 2009 1831 1834
20. B.S. Hoppe, R.C. Nichols, and R.H. Henderson et al. Erectile function, incontinence, and other quality of life outcomes following proton therapy for prostate cancer in men 60 years old and younger Cancer 118 2012 4619 4626
21. P.J. Gray, J.J. Paly, and B.Y. Yeap et al. Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer Cancer 119 2013 1729 1735
22. B.S. Hoppe, J.M. Michalski, and N.P. Mendenhall et al. Comparative Effectiveness Study of Proton Therapy Versus IMRT for Definitive Treatment of Prostate Cancer Based on Patient-Reported Outcomes Int J Radiat Oncol Biol Phys 87 2013 S346
23. M.J. Zelefsky, T. Hollister, and A. Raben et al. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer Int J Radiat Oncol Biol Phys 47 2000 1261 1266 (Pubitemid 30421178)
24. T.N. Eade, E.M. Horwitz, and K. Ruth et al. A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant Int J Radiat Oncol Biol Phys 71 2008 338 345
25. R. Kotecha, Y. Yamada, and X. Pei et al. Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer Brachytherapy 12 2013 44 49
26. R.B. Wilder, G.A. Barme, and R.F. Gilbert et al. Preliminary results in prostate cancer patients treated with high-dose-rate brachytherapy and intensity modulated radiation therapy (IMRT) vs. IMRT alone Brachytherapy 9 2010 341 348
27. I. Deutsch, M.J. Zelefsky, and Z. Zhang et al. Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT Brachytherapy 9 2010 313 318
28. O. Marina, G.S. Gustafson, and L.L. Kestin et al. Comparison of dose-escalated, image-guided radiotherapy vs. dose-escalated, high-dose-rate brachytherapy boost in a modern cohort of intermediate-risk prostate cancer patients Brachytherapy 2013 Jul 18 pii: S1538-4721(13)00280-8. doi: 10.1016/j.brachy.2013.05.004 [Epub ahead of print] PubMed PMID: 23871661
29. S.A. Vora, W.W. Wong, and S.E. Schild et al. Outcome and toxicity for patients treated with intensity modulated radiation therapy for localized prostate cancer J Urol 190 2013 521 526
30. J.M. Michalski, K. Bae, and M. Roach et al. Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study Int J Radiat Oncol Biol Phys 76 2010 14 22
31. C. Vargas, A. Fryer, and C. Mahajan et al. Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 70 2008 744 751 (Pubitemid 351199706)
32. J.M. Michalski, H. Gay, and A. Jackson et al. Radiation dose-volume effects in radiation-induced rectal injury Int J Radiat Oncol Biol Phys 76 2010 S123 S129
33. T. Pickles, and P. Graham What happens to testosterone after prostate radiation monotherapy and does it matter? J Urol 167 2002 2448 2452 (Pubitemid 34533143)
34. E.K. Oermann, S. Suy, and H.N. Hanscom et al. Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer J Hematol Oncol 4 2011 12
35. R.C. Nichols Jr., C.G. Morris, and B.S. Hoppe et al. Proton radiotherapy for prostate cancer is not associated with post-treatment testosterone suppression Int J Radiat Oncol Biol Phys 82 2012 1222 1226
36. W.J. Kil, R.C. Nichols Jr., and B.S. Hoppe et al. Hypofractionated passively scattered proton radiotherapy for low- and intermediate-risk prostate cancer is not associated with post-treatment testosterone suppression Acta Oncol 52 2013 492 497
37. C. Shah, T.B. Lanni Jr., and M.I. Ghilezan et al. Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treatment of low/intermediate prostate cancer Brachytherapy 11 2012 441 445
38. T. Mizowaki, K. Hatano, and M. Hiraoka Surveillance on interfacility differences in dose-prescription policy of intensity-modulated radiation therapy plans for prostate cancer J Radiat Res 53 2012 608 614
39. S. Arcangeli, B. Saracino, and M.G. Petrongari et al. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area Radiother Oncol 84 2007 148 155 (Pubitemid 47284530)
40. J. Vainshtein, E. Abu-Isa, and K.B. Olson et al. Randomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: implications for focal therapy Radiat Oncol 7 2012 82